The world’s first AB-BNCT system obtained an approval from Japanese government
We are pleased to announce that the world’s first AB-BNCT system (BNCT System NeuCure™ & BNCT dose calculation program NeuCure™ Dose Engine, Sumitomo Heavy Industries, Ltd.) obtained medical device approval from Japan Ministry of Health, Labor and Welfare on March 11, 2020.
Clinical application will start once STELLA PHARMA CORPORATION obtains the boron-based drug application approval. We expect to commence treatment for international patients with advanced inoperable or recurrent head and neck cancer in June 2020. Treatment packages and fees will be announced shortly.